This growth was generated by the full year effect of Exelon ® and the continued performance of our recent launches, including Lenvima ®, Halaven ® and Rembre ® in Colombia. “I am excited to announce that we delivered another record year in 2022, with revenues of over $290,000, an increase of 21% over last year and record adjusted EBITDA of over $54,000, an increase of 42% over last year.
Purchased an additional 1,279,900 common shares through NCIB for an aggregate cash consideration of $6,577.ġ Adjusted EBITDA is a non-GAPP measure, refer to the definitions below in section “Non-Gaap measures” for additional details.Submitted two branded generic products (palbociclib and pomalidomide) for regulatory approval in Chile and Colombia in Q4-2022.Obtained regulatory approval for Palbocil ® (palbociclib) in Argentina in Q4-22.In-license three branded generics products for key territories in LATAM.Submitted tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT) to ANVISA for regulatory approval in Brazil and Colombia in Q4-22 and Argentina in Q1-23.Transferred marketing authorization of Exelon ® (rivastigmine) and assumed commercial activities in Brazil, Colombia, Argentina, Mexico, Chile, Peru, Ecuador, Canada and re-launched Exelon ® in Brazil and certain other LATAM countries.
Relaunched AKYNZEO ® in Canada, Brazil and Argentina, and ALOXI ® oral/IV in Canada in second half of 2022.Entered into an exclusive license, distribution and supply agreement with Helsinn for AKYNZEO ® oral/IV (netupitant/palonosetron/fosnetupitant/palonosetron) in Canada, Brazil and select LATAM countries and ALOXI ® oral/IV (palonosetron) in Canada in May 2022.Entered into exclusive license and supply agreements with Rigel Pharmaceuticals to commercialize fostamatinib in LATAM in May 2022.
0 kommentar(er)
